Literature DB >> 3007760

N-substituent modulation of opiate agonist/antagonist activity in resolved 3-methyl-3-(m-hydroxyphenyl)piperidines.

A Cheng, E Uyeno, W Polgar, L Toll, J A Lawson, J I DeGraw, G Loew, A Camerman, N Camerman.   

Abstract

A series of 3-methyl-3-(m-hydroxyphenyl)piperidines with N-substituent variations have been synthesized and resolved, and an X-ray crystal structure of one analogue was determined. The compounds have been characterized, pharmacologically, by detailed opiate receptor binding studies and determination of in vivo analgesia and opiate antagonism. The results indicate that all compounds bind with high selectivity and moderate affinity to mu-receptors with no qualitative difference between enantiomeric pairs. By contrast a striking difference in activities is found, with the (-) enantiomers being pure agonists and the (+) enantiomers having both agonist and antagonist activity. The effect of N-substituents on relative agonist and antagonist potency does not mimic that of fused ring opiates with the N-phenethyl compound, the most potent antagonist. These results together with the X-ray structure obtained suggest that agonist and antagonist activity is initiated by a bimodel binding of the compounds in two different orientations at the mu-receptor site.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007760     DOI: 10.1021/jm00154a018

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Synergistic Peptide and Gold Catalysis: Enantioselective Addition of Branched Aldehydes to Allenamides.

Authors:  Leo D M Nicholls; Helma Wennemers
Journal:  Chemistry       Date:  2021-10-13       Impact factor: 5.020

2.  In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential.

Authors:  Taline V Khroyan; Andrea Cippitelli; Nicholas Toll; John A Lawson; William Crossman; Willma E Polgar; Lawrence Toll
Journal:  Front Psychiatry       Date:  2017-04-12       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.